Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics

非天然产品公司获得4500万美元B轮融资，用于推进大环肽治疗药物的发展。

Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors

由The Venture Collective领投，Merck Global Health Innovation Fund、Artis Ventures、First Spark Ventures、argenx、Droia Ventures以及现有投资者参投。

SANTA CRUZ, Calif., March 16, 2026-- Unnatural Products, a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, today announced the closing of a $45 million Series B financing led by The Venture Collective (TVC), with participation from argenx, Droia Ventures and existing investors Merck Global Health Innovation Fund, Artis Ventures, and First Spark Ventures..

加利福尼亚州圣克鲁兹，2026年3月16日——Unnatural Products是一家开发生物技术公司，专注于开发口服大环肽以解决以往无法成药的靶点，该公司今日宣布完成了由The Venture Collective（TVC）领投的4500万美元B轮融资，参投方包括argenx、Droia Ventures以及现有投资者默克全球健康创新基金、Artis Ventures和First Spark Ventures。

The funding will support development of the company’s proprietary drug discovery platform and advance its pipeline of macrocyclic peptide therapeutics designed to address historically difficult-to-drug or “undruggable” targets.

这笔资金将用于支持该公司专有的药物发现平台的开发，并推进其旨在解决历史上难以成药或“不可成药”靶点的宏观环肽治疗药物管线。

Last month, Unnatural Products announced a licensing agreement with Novartis to develop macrocyclic peptide therapeutics for historically undruggable cardiovascular targets, including up to $100 million upfront and up to $1.7 billion in total potential milestones.

上个月，Unnatural Products 宣布与诺华达成许可协议，开发针对历史上无法成药的心血管靶点的大环肽治疗药物，包括高达 1 亿美元的预付款和总计高达 17 亿美元的潜在里程碑付款。

“Macrocyclic peptides represent a powerful new therapeutic modality,” said Cameron Pye, Chief Executive Officer and Co-Founder, Unnatural Products. “Our platform unlocks the precision of biologics with the delivery advantages of small molecules, enabling us to target complex intracellular pathways that have historically been out of reach.

“大环肽代表了一种强大的新型治疗方式，”非天然产品公司的首席执行官兼联合创始人卡梅伦·派伊表示。“我们的平台结合了生物制剂的精准性与小分子递送的优势，使我们能够靶向历史上一直难以触及的复杂细胞内通路。”

We can also provide oral solutions to targets only currently addressable with costly injectables. This financing allows us to accelerate development of our pipeline and advance our lead programs toward the clinic.”.

我们还可以为目前只能通过昂贵的注射剂才能解决的目标提供口服解决方案。这笔资金使我们能够加速推进我们的研发管线，并推动我们的主要项目走向临床。”

“Unnatural Products has developed a differentiated platform capable of unlocking new therapeutic opportunities across challenging disease targets,” said Nicholas Shekerdemian, Founding Partner, The Venture Collective. “We believe the company’s approach to engineering synthetic macrocyclic peptides has the potential to create an important new class of medicines, and we are excited to support the team as they expand their pipeline and move programs toward clinical development.”.

“Unnatural Products 开发了一个差异化的平台，能够针对棘手的疾病靶点挖掘新的治疗机会，”The Venture Collective 创始合伙人尼古拉斯·谢克德米安表示。“我们认为该公司在合成大环肽工程方面的创新方法有潜力创造一类重要的新型药物，我们非常高兴支持该团队扩展其研发管线，并推动项目走向临床开发。”

Unnatural Products has developed an integrated discovery platform capable of repeatedly engineering synthetic macrocyclic peptides at scale. Macrocyclic peptides combine key attributes of both biologics and small molecules, enabling highly selective binding while retaining the potential for cell permeability and oral delivery..

非天然产品公司开发了一个综合发现平台，能够大规模反复设计合成大环肽。大环肽结合了生物制品和小分子的关键特性，既能够实现高选择性结合，又保留了细胞渗透性和口服递送的潜力。

The company’s platform integrates advanced computational design, automated chemistry, and high-throughput biological testing to rapidly move from initial discovery hits to optimized drug candidates. The company is also advancing a pipeline of macrocyclic peptide therapeutics for the treatment of cardiometabolic, inflammatory and immunological diseases..

公司的平台整合了先进的计算设计、自动化化学和高通量生物测试，能够快速从初步发现的候选物推进到优化的药物候选物。公司还在推进一条用于治疗心脏代谢、炎症和免疫疾病的大环肽治疗药物管线。

Unnatural Products has also established collaborations with leading pharmaceutical and biotechnology companies including Novartis, Merck, BridgeBio and argenx to apply its macrocyclic platform across multiple therapeutic areas.

非天然产品公司还与包括诺华、默克、BridgeBio和argenx在内的领先制药和生物技术公司建立了合作关系，以将其大环平台应用于多个治疗领域。

About Unnatural Products, Inc.

关于非天然产品公司

Unnatural Products, Inc. (UNP), a Santa Cruz, California biotech company, has developed a platform that addresses the complexities of medicinal chemistry in the macrocycle space through a combination of parallel experimentation and machine learning. Founded by macrocycle pioneers whose academic work uncovered how Nature’s macrocycles work, UNP is developing a portfolio of therapeutic macrocycles against high-value and traditionally difficult-to-drug targets.

非天然产品公司（Unnatural Products, Inc.，简称UNP），一家位于加利福尼亚州圣克鲁斯的生物技术公司，开发了一个平台，通过平行实验与机器学习相结合，解决了大环空间中药物化学的复杂性问题。该公司由大环先锋创立，他们的学术研究揭示了自然界大环分子的作用机制，UNP正在开发针对高价值且传统上难以成药靶点的治疗性大环分子组合。

For more information, visit www.unnaturalproducts.com..

欲了解更多信息，请访问 www.unnaturalproducts.com。

For partnering opportunities, email: contact@unnaturalproducts.com.

如需合作机会，请发送邮件至：contact@unnaturalproducts.com。

Contact:

联系人：

Media Contact

媒体联系人

Kimberly Ha

金伯利·哈

KKH Advisors

KKH顾问公司

917-291-5744

917-291-5744

kimberly.ha@kkhadvisors.com

kimberly.ha@kkhadvisors.com